EBIT: Income before interest and taxes.
Cyclacel Pharmaceuticals, Inc. (CYCC) had EBIT of $-25.45M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$0.42M |
|
$-22.76M |
|
-- |
|
$0.42M |
|
$25.87M |
|
$-25.45M |
|
$-0.10M |
|
$-25.55M |
|
$-25.55M |
|
$-22.55M |
|
$-22.55M |
|
$-22.55M |
|
$-22.55M |
|
|
EBIT |
$-25.45M |
$-25.42M |
|
0.85M |
|
0.85M |
|
$-26.75 |
|
$-26.75 |
|
| Balance Sheet Financials | |
$7.44M |
|
$0.01M |
|
$1.36M |
|
$8.80M |
|
$8.16M |
|
-- |
|
$0.04M |
|
$8.20M |
|
$0.61M |
|
$0.61M |
|
$0.61M |
|
1.06M |
|
| Cash Flow Statement Financials | |
$-16.11M |
|
$-0.01M |
|
$0.85M |
|
$18.34M |
|
$3.38M |
|
$-14.97M |
|
$1.47M |
|
-- |
|
$-0.20M |
|
| Fundamental Metrics & Ratios | |
0.91 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-6060.24% |
|
-6060.24% |
|
-6052.86% |
|
-6083.57% |
|
-5418.10% |
|
$-16.12M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
-- |
|
-- |
|
-3715.91% |
|
-3715.81% |
|
-256.16% |
|
-3715.82% |
|
$0.57 |
|
$-18.94 |
|
$-18.94 |
|